1352 Il28b-Cc Genotype-Related Gene Expression During Treatment of Chronic Hepatitis C (Ch-C) With Pegylated Interferon-Alfa (Peg-Ifn) and Ribavirin (Rbv): Potential Mechanisms for Sustained Virologic Response (Svr)

Management of chronic hepatitis C infection in children

“…Whereas standard PEG-IFN and RBV results in an SVR in 30-50% of adult patients with genotype 1 infection [33], the addition of either boceprevir or telaprevir as part of a triple therapy regimen is associated with significant improvements in SVR rates (Table 5). Two phase III randomized controlled trials of telaprevir (ADVANCE and REALIZE) and boceprevir (SPRINT-2 and RESPOND-2) in treatment-naive and previously treated patients, respectively, demonstrated an increase in SVR when telaprevir was used in combination with PEG-IFN and ribavarin [34,35]. Phase III studies conducted with boceprevir (SPRINT-2 and RESPOND-2) have shown similar results [36 & ,37].…”